The Scientist

» drug development

Most Recent

image: Infographic: Repurposing Strategies

Infographic: Repurposing Strategies

By Anna Azvolinsky | January 1, 2017

Novel uses for existing and failed drugs may save companies time and money in bringing new therapeutics to market.

0 Comments

image: Biomedical Research Bill Approved in House

Biomedical Research Bill Approved in House

By Ben Andrew Henry | December 1, 2016

The 21st Century Cures Act could provide funds to federal research agencies for the decade and accelerate the drug approval process.

1 Comment

image: Oligonucleotide Therapeutics Near Approval

Oligonucleotide Therapeutics Near Approval

By Catherine Offord | December 1, 2016

Successful late-stage clinical trials could mark the maturation of a new drug development platform, but the path to commercialization is not without hurdles.

0 Comments

image: New Support for Experimental Alzheimer’s Drug

New Support for Experimental Alzheimer’s Drug

By Jef Akst | November 2, 2016

Merck’s verubecestat, which is currently being tested in two Phase 3 studies, is safe, according to newly published Phase 1 data.

2 Comments

image: Cuban-U.S. Research Collaborations Easier Now

Cuban-U.S. Research Collaborations Easier Now

By Kerry Grens | October 18, 2016

President Obama’s executive actions remove some of the red tape for American and Cuban scientists to work together.

0 Comments

image: Pet Meds Adapted from Human Therapies

Pet Meds Adapted from Human Therapies

By Jenny Rood | October 1, 2016

Companies focused on developing treatments for dogs, cats, and horses are bringing a diverse array of products to the pet medicine market.

0 Comments

image: Q&A: From FDA to Industry

Q&A: From FDA to Industry

By Kerry Grens | September 27, 2016

Among a subset of US Food and Drug Administration regulators who leave the agency, more than half go to work for pharmaceutical companies, researchers report.

1 Comment

image: Allergan’s Buying Spree Rolls On

Allergan’s Buying Spree Rolls On

By Bob Grant | September 21, 2016

The Ireland-based pharma company makes a $1.7 billion offer to acquire Tobira Therapeutics, a US firm developing liver disease drugs.

0 Comments

image: Feds Demand More Clinical Trial Reporting

Feds Demand More Clinical Trial Reporting

By Kerry Grens | September 19, 2016

Expanded US Health and Human Services rules will require the results of more human studies to be made public.

1 Comment

image: Allergan Set to Buy Vitae

Allergan Set to Buy Vitae

By Bob Grant | September 16, 2016

The Irish drugmaker has made a $639 million dollar offer to buy the US-based biopharma.

0 Comments

Popular Now

  1. Sci-Hub Loses Domains and Access to Some Web Services
  2. Stem Cell Vaccine Protects Mice From Cancer
  3. Nobel Prize–Winning Biologist Dies
  4. CDC: Flu Vaccine 36 Percent Effective So Far
AAAS